CREBBP and acute myeloid leukemia: More recently, a CREBBP and EP300 bromodomain inhibitor (CCS1477) has been demonstrated to have potent anti-proliferative and pro-differentiation activity in AML cell lines and primary patient samples (111); a first-in-human phase 1 study has commenced in castration-resistant prostate cancer (NCT03568656) and a related study will shortly commence in patients with multiple hematologic malignancies, including AML.